Post-Market Surveillance Report (PMSR) is the report that manufacturers of Class I medical devices must prepare under Article 85 of EU MDR 2017/745. It summarizes the results and conclusions of post-market surveillance data analysis, plus any corrective or preventive actions taken, and confirms the device benefit-risk profile remains acceptable.
What is a Post-Market Surveillance Report (PMSR)?
The PMSR sits in the post-market phase of the device lifecycle, after a product reaches the EU market. It is one of the post-market surveillance outputs defined by EU MDR 2017/745, alongside the Periodic Safety Update Report (PSUR) and Post-Market Clinical Follow-up (PMCF). All of them draw on the same post-market surveillance plan set out in Article 84.
Article 85 assigns the PMSR to Class I devices, the lowest risk class. Manufacturers of Class IIa, IIb, and III devices prepare a PSUR instead. The PMSR forms part of the technical documentation described in Annex III. It must be updated when necessary and made available to a competent authority on request, but it does not have to be submitted to a notified body.
Why the Post-Market Surveillance Report (PMSR) matters in medical device development
Passing conformity assessment is not the end of a manufacturer’s safety obligations. Real-world use surfaces failure modes, use errors, and complaint patterns that bench testing and clinical evaluation cannot fully predict. The PMSR is the mechanism that forces a structured review of that evidence for a Class I device.
Regulators read a missing or thin report as a signal of a weak quality system. During an audit or an unannounced inspection, an absent PMSR, or one that restates the plan without any analysis, invites findings against ISO 13485 and the MDR. Those findings can stall CE certificate activity and slow new submissions.
There is a commercial angle as well. A report that flags a rising complaint rate, or a shift in the benefit-risk balance, gives an OEM early warning to act before a field safety corrective action becomes unavoidable. Catching a trend on paper is far cheaper than a recall.
What the Post-Market Surveillance Report (PMSR) must contain
Article 85 keeps the required content lean, and each element carries weight:
- A summary of PMS data analysis: the results and conclusions drawn from data collected under the Article 84 PMS plan: complaints, service records, returns, literature, registry data, and similar-device information.
- Preventive and corrective actions: a rationale and description of any CAPA triggered by post-market findings during the reporting period.
- Benefit-risk confirmation: a statement, supported by the data, that the benefit-risk determination held in the technical documentation and the ISO 14971 risk management file still stands.
The report is retrospective. It covers a defined period and reads as evidence that the manufacturer runs its PMS system rather than just describing it. Good practice ties each conclusion back to a named data source and to the risk file, so an assessor can trace the logic. As EUDAMED registration becomes mandatory, competent authorities will reach these outputs through the electronic system, which raises the bar on internal consistency.
Common challenges and best practices
The frequent mistake is treating the PMSR as an annual formality written the week before an audit. A report assembled from memory, with no live data feed, tends to conclude that everything is fine regardless of what the complaint log actually shows. Assessors notice.
Teams that do this well set up data collection during the PMS planning stage, not after. They define the indicators, thresholds, and sources up front, so writing the report means summarizing existing analysis instead of starting one. They also keep the cadence honest. Article 85 says “when necessary,” and for a stable low-risk device, that often means a defined annual review, but a spike in complaints should trigger an off-cycle update.
One more trap is confusing the PMSR with the PSUR. The two share a data backbone, but the PSUR carries extra content such as sales volume and usage estimates and follows a fixed update frequency. Applying the wrong template to the wrong device class shows up regularly as an audit finding.
How SJML helps with the Post-Market Surveillance Report (PMSR)
SJML runs post-market surveillance as part of its Compliance-as-a-Service offering. The QARA team supports PMS and PMCF planning, then PSUR and PMSR preparation, drawing on complaints handling, vigilance, and field safety corrective action workflows. Root-cause analysis feeds CAPA, and findings connect back to the ISO 14971 risk file and technical documentation, including EUDAMED readiness. For OEMs scaling from a first Class I device to a broader portfolio, this keeps post-market reporting consistent across the range.
Frequently asked questions
Manufacturers of Class I medical devices under EU MDR 2017/745 must prepare a PMSR. Higher-risk devices in Class IIa, IIb, and III require a Periodic Safety Update Report (PSUR) instead. Both draw on the same post-market surveillance plan, but the PMSR is the lighter-weight output reserved for the lowest-risk class.
Both summarize post-market surveillance data and any resulting corrective and preventive actions. The difference is device class and depth. The PMSR applies to Class I devices and is not submitted to a notified body. The PSUR applies to Class IIa, IIb, and III devices, adds sales and usage data, and follows a fixed annual or biennial update frequency.
EU MDR Article 85 requires the PMSR to be updated “when necessary” rather than on a fixed schedule. In practice, manufacturers of a stable Class I device usually define a periodic review, often annual, in their PMS procedure. A significant change, such as a rise in complaints or a new risk, should trigger an update outside that cycle.
No. The PMSR is kept as part of the technical documentation and made available to a competent authority on request, but it is not proactively submitted to a notified body. This differs from the PSUR for higher-risk devices, which a notified body reviews. Once EUDAMED is mandatory, these reports will become accessible through that system.
Related terms
- Post-Market Surveillance (PMS)
- Periodic Safety Update Report (PSUR)
- Post-Market Clinical Follow-up (PMCF)
- Vigilance Reporting
- CAPA (Corrective and Preventive Action)
